Prosecution Insights
Prosecution Insights
1 pending office actions • 0 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Invivyd Inc. has 1 pending office action in its portfolio. This action is being reviewed by 1 distinct examiner. There are 0 distinct art units recorded for the company's current pending activity. NATARAJAN, MEERA is the busiest examiner, with 1 busiest examiner pending office action. This single action constitutes the entirety of the company's current prosecution efforts at the USPTO.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NATARAJAN, MEERA | 1 | 62.5% | +18.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18699101 | PHARMACEUTICAL FORMULATIONS COMPRISING ANTI-CORONAVIRUS S PROTEIN ANTIBODIES AND USES THEREOF | NATARAJAN, MEERA | — |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18699101 | PHARMACEUTICAL FORMULATIONS COMPRISING ANTI-CORONAVIRUS S PROTEIN ANTIBODIES AND USES THEREOF | NATARAJAN, MEERA | — | §102DP | Non-Final OA | — | Pending | Apr 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial